There is certainly change in the wind in relation to funded lamotrigine in the future.

PHARMAC have notified that effective 1 October 2019 there will be one fully funded brand.

There is a 5 month transition period from 1 May 2019 to 30 September 2019 where all existing brands will remain listed and fully funded at existing schedule prices.

This provides a small window of opportunity for pharmacy to make additional margin for a period of time leading up to the 30 September 2019. Yes all patients will need to transition to the sole supply brand Logem, but not immediately.

In association with Teva we are able to offer you a 20% discount on all purchases of Lamotrigine-Arrow Tablets 25 mg, 50mg and 100 mg 56 packs, plus they are supplied on a Sale or Return basis. The Teva statement as follows:-

“All Lamotrigine-Arrow stock is on Sale or Return until 30 September 2019. Any full packs remaining in pharmacy on the 1st October 2019 may be returned to your wholesaler no later than Friday 11th October 2019 for credit”

This is certainly a win for pharmacy that continue to dispense Teva brand until 30 September 2019 or close to it.

Click here to access the analysis clearly showing you the advantage of doing what is proposed.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author